Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of a Single Dose of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of a Single Dose of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2019

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Cachexia; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2018 Results (n=67) published in the American Journal of Respiratory and Critical Care Medicine.
    • 18 May 2016 Primary endpoint has been met. (Change in thigh muscle volume compare to placebo as measured by MRI), as per an abstract presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top